MLH NCORP receives NCI award for clinical trial enrollments

 By Donna Loyle, LIMR communications specialist

The Main Line Health cancer clinical trials team was awarded a Silver Certificate of Excellence from the National Cancer Institute (NCI) for their exceptional achievement in patient enrollments in the NCI Community Oncology Research Program (NCORP).

Since 2014, the team has enrolled 133 patients: 54 in cancer control trials and 79 in cancer treatment trials. Because MLH is one of only 34 NCORP community sites in the US, our patients have access to state-of-the-art clinical trials and new cancer treatments before they become available to the general public. MLH NCORP is led by Principal Investigator Albert DeNittis, MD, Chief of Radiation Oncology at Lankenau Medical Center.

“We are proud to have been awarded a Silver Certificate from NCI for our impressive record of patient enrollments in NCORP,” said Dr. DeNittis. “Research plays a vital role in patient outcomes. Based on research findings, we are able to offer patients at Main Line Health the latest treatment options for their particular medical conditions. Our involvement in the program also means that our cancer patients can play a more active role in their health care.”


For more on NCORP, visit

This entry was posted in Clinician News and tagged , . Bookmark the permalink.

Leave a Reply

Your email address will not be published.